As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories.

“Closing this collaboration with Zydus strengthens our balance sheet and, critically, secures dedicated U.S. manufacturing capacity at a pivotal moment for Agenus,” continued Armen. “With these foundations in place, our focus in 2026 is disciplined execution—advancing our Phase III program, broadening paid patient access through authorized pathways, and progressing toward regulatory submission supported by one of the most substantial clinical datasets generated in [microsatellite stable] MSS colorectal cancer.”

Following the closing, the Emeryville and Berkeley, CA, biologics manufacturing facilities will be transferred to Zydus and housed under a newly formed subsidiary named Zylidac Bio. Agenus has secured committed manufacturing capacity at these U.S. sites to support BOT+BAL supply needs for its clinical trials, global access programs, and future commercialization.